Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Articles

173287 items
12:00 AM, Apr 18, 1994  |  BC Week In Review | Company News  |  Deals

Amylin deal

The San Diego company extended its collaboration with Glaxo Holdings plc for the development of medicines to treat diabetes, high blood pressure and obesity. In October 1991 the companies entered into a three-year agreement to...
12:00 AM, Apr 18, 1994  |  BC Week In Review | Company News  |  Deals

GenPharm International Inc. deal

GenPharm plans to derive IgA preparations after immunizing the animals with specific antigens. The company is developing IgA-based drugs for oral treatment of specific gastrointestinal infections of viral or bacterial origin. The university will conduct...
12:00 AM, Apr 18, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

RMP-7 bradykinin agonist for drug delivery data

ALKS reported animal data showing increase in permeability of the blood-brain barrier, with a preferential increase near areas of damaged brain tissue. At the meeting of the American Association of Neurological Surgeons, university researchers presented...
12:00 AM, Apr 18, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

Annamycin data

The Woodlands, Texas, company published animal results in Cancer Research, showing that annamycin both in suspension and in a liposomal version was more effective than doxorubicin, the standard anthracycline chemotherapeutic, in prolonging survival of mice...
12:00 AM, Apr 18, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

105AD7 vaccine data

IMCL presented data from a Phase I trial showing that 13 patients with advanced colorectal cancer who were immunized with intramuscular doses of 100 µg or 200 µg of 105AD7 had longer median survival than...
12:00 AM, Apr 18, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

MSI-78 anti-infective: To start the first of two Phase III trials

MAGN has not yet decided whether it will proceed with the drug in trials for impetigo, after it failed to produce statistically significant results in a pivotal Phase IIb/III trial for that indication. Magainin Pharmaceuticals...
12:00 AM, Apr 18, 1994  |  BC Week In Review | Clinical News  |  Preclinical Results

MicroProbe preclinical data

MPRO (Bothell, Wash.) presented animal data with its new agents, including lead compound MPC-467. The oligonucleotides don't act as antisense agents. In vitro, the agents caused large vacuoles to appear in liver tumor cells, and...
12:00 AM, Apr 18, 1994  |  BC Week In Review | Clinical News  |  Preclinical Results

Matrix Pharma preclinical data

MATX (Menlo Park, Calif.) presented animal data on a new, non-protein delivery system designed for cancer drugs that are not easily dissolved in water, and on its IntraDose system in pancreatic cancer. Using the...
12:00 AM, Apr 18, 1994  |  BC Week In Review | Company News  |  Deals

Zonagen deal

The Woodlands, Texas, company acquired rights from Gamogen Inc., a subsidiary of ReproMed Systems Inc., to develop an oral treatment for male impotency. ZONA said the undisclosed product is approved in the U.S. for another...
12:00 AM, Apr 18, 1994  |  BC Week In Review | Clinical News  |  Clinical Results

Macromol oral delivery system data

The U.K. company reported results in a total of 135 healthy human volunteers at two recent meetings in Europe, showing reductions in a byproduct of bone breakdown after oral doses of peptide salmon calcitonin. Until...

Pages